Sunvozertinib tablets | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Medicine type: Chemical medicine
Therapeutic area: Oncology
Indications recorded in the public source: Treatment of adults with locally advanced or metastatic NSCLC with a confirmed EGFR exon 20 insertion mutation whose disease progressed during or after platinum-containing chemotherapy, or who could not tolerate platinum-containing chemotherapy.
Indication source and scope: Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Limited to adults with locally advanced or metastatic NSCLC with a confirmed EGFR exon 20 insertion mutation after progression during or after platinum chemotherapy, or intolerance to platinum chemotherapy.
Insurance period: 2025-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions